en
Scientific article
English

Safety and efficacy of intravenously administered cidofovir in adult haematopoietic cell transplant recipients: a retrospective multicentre cohort study

Published inThe journal of antimicrobial chemotherapy, vol. 76, no. 11, p. 3020-3028
Publication date2021-10-11
Abstract

Objectives: To evaluate the safety and efficacy of cidofovir for the treatment of double-stranded DNA (dsDNA) viral infections following allogeneic haematopoietic cell transplant (HCT).

Methods: This was a retrospective multicentre cohort study including adult HCT recipients who received ≥1 dose of IV-administered cidofovir for any dsDNA viral infection from 2006 to 2019. The objectives were to describe the rate of and risk factors for nephrotoxicity and virological response by the end of treatment (EOT).

Results: We included 165 patients from nine centres. Cidofovir was administered at 5 mg/kg/week (N = 115; 69.7%), 1 mg/kg/week (18; 10.9%), 3 mg/kg/week (12; 7.3%) or 1 mg/kg three times/week (11; 6.7%). Cidofovir was administered for adenovirus, cytomegalovirus (CMV) and BK virus infection in 75 (45.5%), 64 (38.8%) and 51 (30.9%) patients, respectively. Among 158 patients with renal function data at baseline and EOT, 40 (25.3%) developed nephrotoxicity. In multivariable analyses, age (OR 1.04; P = 0.05), weight (OR 1.05; P = 0.01), CMV infection (OR 3.6; P = 0.02), liposomal amphotericin B (OR 8.06; P = 0.05) and IV voriconazole/posaconazole (OR 13.0; P = 0.003) were predictors of nephrotoxicity. Creatinine concentration was significantly higher at EOT (1.16 ± 0.95 mg/dL) compared with baseline (0.91 ± 0.39 mg/dL; P < 0.001), but improved by 2 weeks (0.91 ± 0.84 mg/dL; P = 0.007) and 4 weeks (0.96 ± 0.89 mg/dL; P = 0.03) post-EOT. Median viral load significantly declined for patients with adenovirus DNAaemia by EOT (P < 0.0001) and for patients with CMV DNAaemia by EOT + 4 weeks (P = 0.003), but not for patients with BK virus DNAaemia.

Conclusions: One in four HCT recipients treated with IV cidofovir developed largely reversible nephrotoxicity. Careful selection of patients and close follow-up of renal function may minimize toxicity.

eng
Keywords
  • Antiviral Agents / adverse effects
  • Cidofovir
  • Cohort Studies
  • Cytosine / therapeutic use
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Humans
  • Organophosphonates / adverse effects
  • Retrospective Studies
  • Transplant Recipients
Citation (ISO format)
STERN, Anat et al. Safety and efficacy of intravenously administered cidofovir in adult haematopoietic cell transplant recipients: a retrospective multicentre cohort study. In: The journal of antimicrobial chemotherapy, 2021, vol. 76, n° 11, p. 3020–3028. doi: 10.1093/jac/dkab259
Main files (1)
Article (Published version)
Secondary files (1)
Identifiers
ISSN of the journal0305-7453
138views
0downloads

Technical informations

Creation03/01/2022 1:25:00 PM
First validation03/01/2022 1:25:00 PM
Update time03/16/2023 7:05:39 AM
Status update03/16/2023 7:05:37 AM
Last indexation05/06/2024 11:16:07 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack